Ionis Pharmaceuticals, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, reporting financial results for the three and nine months ended on that date.
C3is Inc. filed a Form 6-K with the U.S. Securities and Exchange Commission on November 9, 2026, disclosing that the company effected a one-for-5 reverse stock split of its common stock, with the split becoming effective at 11:59 p.m. Eastern time on November 8, …
Vistagen Therapeutics, Inc. filed a Form 8-K on November 9, 2026, announcing a regulatory update following a Type C meeting with the U.S. Food and Drug Administration to discuss potential registrational paths for its lead product candidate, fasedienol, in social anxiety disorder.
Newell Brands Inc. filed a Form 8-K on November 9, 2026, disclosing that its Board of Directors voted on November 4, 2026, to expand the board from eight to nine members and elect William Newlands as a director, effective January 1, 2027.
The New York Stock Exchange filed a notification on November 9, 2026, to remove 3M Co's 1.500% Notes due 2026 from listing and registration under Section 12(b) of the Securities Exchange Act of 1934.
Johnson Varkey, SVP and Chief Information Officer of Waste Management Inc, filed a Form 4 on November 6, 2026, disclosing the sale of 500 shares of common stock on November 5, 2026.
Aqeel Ahmad Fatmi filed an initial statement of beneficial ownership with the SEC on November 9, 2026, disclosing his status as a newly reporting director of Elite Pharmaceuticals Inc /NV/ following a triggering event dated October 28, 2026.
Alarum Technologies Ltd. filed a Form 6-K on November 9, 2026, furnishing updated proxy materials for its Annual General Meeting of Shareholders scheduled for December 30, 2026, superseding materials originally furnished on November 5, 2026.
Bitmine Immersion Technologies, Inc. filed a press release on November 9, 2026, announcing its crypto, cash, and marketable securities holdings totaling $14.3 billion as of November 8, 2026.
Tonix Pharmaceuticals Holding Corp. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting accelerating operating losses alongside significant growth in product revenue.